Xenoport News
Most Popular Xenoport Story
FDA spurns XenoPort's Horizant app
In a setback, the FDA has rejected an application from XenoPort and GlaxoSmithKline to approve the use of Horizant for restless leg syndrome. Regulators pinpointed the potential link of the drug to Read more...
Latest Headlines
- November 8, 2010
- August 27, 2010
- March 8, 2010
- February 19, 2010
- February 18, 2010
- February 5, 2010
- September 17, 2009
- April 27, 2009
- December 2, 2008
- November 10, 2008
- February 28, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
